
    
      This study consisted of two independent parts: Part 1 was conducted first followed by Part 2.
      Part 1 enrolled participants who received ABT-493 and ABT-530 for 12 weeks; Part 2 enrolled
      participants who received ABT-493 and ABT-530 for 8 or 12 weeks. Participants who completed
      or prematurely discontinued the treatment period were followed for 24 weeks to monitor HCV
      RNA to evaluate efficacy and the emergence and persistence of viral variants.
    
  